S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio

Genfit Stock Price, News & Analysis (NASDAQ:GNFT)

$3.18
-0.08 (-2.45%)
(As of 12/4/2023 ET)
Compare
Today's Range
$3.18
$3.19
50-Day Range
$2.97
$3.40
52-Week Range
$2.89
$4.75
Volume
37,487 shs
Average Volume
39,008 shs
Market Capitalization
$158.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Genfit MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
135.8% Upside
$7.50 Price Target
Short Interest
Bearish
0.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.23) to $0.50 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

705th out of 952 stocks

Biological Products, Except Diagnostic Industry

115th out of 155 stocks


GNFT stock logo

About Genfit Stock (NASDAQ:GNFT)

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

GNFT Stock Price History

GNFT Stock News Headlines

GENFIT Reports Third Quarter 2023 Financial Information
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Genfit (NASDAQ: GNFT)
Kepler Capital Keeps Their Buy Rating on Genfit (GNFTF)
GENFIT to Participate in Upcoming Investor Conferences
See More Headlines
Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNFT
Fax
N/A
Employees
154
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$11.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+135.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$28 million
Book Value
$2.00 per share

Miscellaneous

Free Float
47,742,000
Market Cap
$158.46 million
Optionable
Not Optionable
Beta
1.08
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Jean-Francois Mouney (Age 68)
    Co-Founder & Chairman of the Board
    Comp: $401.85k
  • Mr. M. Pascal Prigent (Age 55)
    Chief Executive Officer
    Comp: $609.01k
  • Prof. Bart Staels (Age 60)
    Co-Founder & Chairman of the Scientific Advisory Board
  • Mr. Thomas Baetz (Age 49)
    Chief Financial Officer
  • Mr. Pascal Caisey (Age 55)
    Chief Operating Officer
  • Dr. Meriam Kabbaj Ph.D. (Age 49)
    Chief Technology Officer
  • Dr. Dean W. Hum Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $774.94k
  • Mr. Jean-Christophe Marcoux (Age 45)
    Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG
  • Mr. Laurent Lannoo (Age 53)
    Corporate Secretary & Director of Legal Affairs
  • Ms. Stefanie Magner J.D. (Age 42)
    Chief Compliance Officer & Executive VP of International Legal Affairs














GNFT Stock Analysis - Frequently Asked Questions

Should I buy or sell Genfit stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GNFT shares.
View GNFT analyst ratings
or view top-rated stocks.

What is Genfit's stock price target for 2024?

2 brokers have issued 1 year target prices for Genfit's stock. Their GNFT share price targets range from $4.00 to $11.00. On average, they predict the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 135.8% from the stock's current price.
View analysts price targets for GNFT
or view top-rated stocks among Wall Street analysts.

How have GNFT shares performed in 2023?

Genfit's stock was trading at $4.3890 at the beginning of 2023. Since then, GNFT stock has decreased by 27.5% and is now trading at $3.18.
View the best growth stocks for 2023 here
.

What is Jean-François Mouney's approval rating as Genfit's CEO?

3 employees have rated Genfit Chief Executive Officer Jean-François Mouney on Glassdoor.com. Jean-François Mouney has an approval rating of 29% among the company's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Genfit own?
When did Genfit IPO?

(GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

Who are Genfit's major shareholders?

Genfit's stock is owned by a number of institutional and retail investors. Top institutional shareholders include O Shaughnessy Asset Management LLC (0.03%).

How do I buy shares of Genfit?

Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GNFT) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -